All Stories

  1. Development of macrocyclic peptide inhibitors of Mycobacterium tuberculosis MurF via mRNA display with genetic reprogramming
  2. Characterization of PPE19 as a novel mediator of Mycobacterium tuberculosis -macrophage interactions
  3. Florasulam Is a Potent Inhibitor of Mycobacterium tuberculosis Acetohydroxyacid Synthase and Possesses In Vivo Antituberculosis Activity
  4. The fall of the mycobacterial cell wall: interrogating peptidoglycan synthesis for novel anti-TB agents
  5. Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis
  6. Phenotypic‐Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis
  7. Marine sponge microbe provides insights into evolution and virulence of the tubercle bacillus
  8. A Chimeric ORF Fusion Phenotypic Reporter for Cryptococcus neoformans
  9. Identification of Axinellamines A and B as Anti-Tubercular Agents
  10. Synthesis of steroidal inhibitors for Mycobacterium tuberculosis
  11. TcrXY is an acid-sensing two-component transcriptional regulator of Mycobacterium tuberculosis required for persistent infection
  12. Mycobacterium tuberculosis Deficient in PdtaS Cytosolic Histidine Kinase Displays Attenuated Growth and Affords Protective Efficacy against Aerosol M. tuberculosis Infection in Mice
  13. Reassessing the putative molecular Target(s) of potent antitubercular 2-(Alkylsulfonyl)acetamides
  14. seco-1-Azacubane-2-carboxylic Acid: Derivative Scope and Comparative Biological Evaluation
  15. Synthesis and antibacterial activity of 6″-decanesulfonylacetamide-functionalised amphiphilic derivatives of amikacin and kanamycin
  16. TcrXY is an acid-sensing two-component transcriptional regulator of Mycobacterium tuberculosis and a novel target for enhanced TB therapy
  17. Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria
  18. Discovery of Anti‐tubercular Analogues of Bedaquiline with Modified A‐, B‐ and C‐Ring Subunits
  19. Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection
  20. Two‐component sensor histidine kinases of Mycobacterium tuberculosis : Beacons for niche navigation
  21. Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles
  22. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis
  23. Analogues of the Herbicide, N-Hydroxy-N-isopropyloxamate, Inhibit Mycobacterium tuberculosis Ketol-Acid Reductoisomerase and Their Prodrugs Are Promising Anti-TB Drug Leads
  24. The antimicrobial potential of cannabidiol
  25. Discovery of a Pyrimidinedione Derivative with Potent Inhibitory Activity against Mycobacterium tuberculosis Ketol–Acid Reductoisomerase
  26. Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit
  27. GPR183 Regulates Interferons, Autophagy, and Bacterial Growth During Mycobacterium tuberculosis Infection and Is Associated With TB Disease Severity
  28. Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
  29. Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface
  30. Structures of fungal and plant acetohydroxyacid synthases
  31. Discovery, Synthesis and Evaluation of a Ketol‐Acid Reductoisomerase Inhibitor
  32. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering
  33. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering
  34. Mycobacterium tuberculosis requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism
  35. Total Synthesis of the Antimalarial Ascidian Natural Product Albopunctatone
  36. Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity
  37. Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase
  38. Homologous alignment cloning: a rapid, flexible and highly efficient general molecular cloning method
  39. Use of Soluble Extracellular Regions of MmpL (SERoM) as Vaccines for Tuberculosis
  40. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection
  41. Endopeptidase PepO Regulates the SpeB Cysteine Protease and Is Essential for the Virulence of Invasive M1T1 Streptococcus pyogenes
  42. Thioamide Derivative of the Potent Antitubercular 2-(Decylsulfonyl)acetamide is Less Active Against Mycobacterium tuberculosis, but a More Potent Antistaphylococcal Agent
  43. Isothermal Point Mutation Detection: Toward a First-Pass Screening Strategy for Multidrug-Resistant Tuberculosis
  44. Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic Escherichia coli
  45. The PerR-Regulated P1B-4-Type ATPase (PmtA) Acts as a Ferrous Iron Efflux Pump in Streptococcus pyogenes
  46. Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis
  47. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models
  48. Saccharomyces cerevisiae Acetohydroxyacid Synthase in complex with bensulfuron methyl
  49. Commercial Herbicides Can Trigger the Oxidative Inactivation of Acetohydroxyacid Synthase
  50. Naked-Eye Colorimetric and Electrochemical Detection of Mycobacterium tuberculosis—toward Rapid Screening for Active Case Finding
  51. Rapid DNA detection of Mycobacterium tuberculosis-towards single cell sensitivity in point-of-care diagnosis
  52. Rapid, Single-Cell Electrochemical Detection of Mycobacterium tuberculosis Using Colloidal Gold Nanoparticles
  53. Host–pathogen interaction during bacterial vaccination
  54. Structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease
  55. First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity
  56. Manganese Homeostasis in Group A Streptococcus Is Critical for Resistance to Oxidative Stress and Virulence
  57. Crystal Structure of E. coli XGPRT in complex with (3R,4S)-4-(Guanin-9-yl)-3-hydroxypyrrolidin-1-N-ylacetylphosphonic acid
  58. ZapE Is a Novel Cell Division Protein Interacting with FtsZ and Modulating the Z-Ring Dynamics
  59. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines
  60. Inhibition of the Escherichia coli 6-Oxopurine Phosphoribosyltransferases by Nucleoside Phosphonates: Potential for New Antibacterial Agents
  61. Plasmin(ogen) Acquisition by Group A <b><i>Streptococcus</i></b> Protects against C3b-Mediated Neutrophil Killing
  62. Inhibition studies on Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmU)
  63. Host Cell–Induced Components of the Sulfate Assimilation Pathway Are Major Protective Antigens of Mycobacterium tuberculosis
  64. The Secreted Lipoprotein, MPT83, of Mycobacterium tuberculosis Is Recognized during Human Tuberculosis and Stimulates Protective Immunity in Mice
  65. Elucidation ofMycobacterium tuberculosisType II Dehydroquinase Inhibitors using a Fragment Elaboration Strategy
  66. Synthesis and evaluation of M. tuberculosis salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site
  67. Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis
  68. Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads
  69. Immunity toMycobacterium tuberculosis
  70. Synthesis and Evaluation of Potent Ene-yne Inhibitors of Type II Dehydroquinases as Tuberculosis Drug Leads
  71. Tetrahydrolipstatin Inhibition, Functional Analyses, and Three-dimensional Structure of a Lipase Essential for Mycobacterial Viability
  72. Modulation of Shigella virulence in response to available oxygen in vivo
  73. Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine
  74. Cutinase‐like proteins of Mycobacterium tuberculosis : characterization of their variable enzymatic functions and active site identification
  75. Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis
  76. Non-motile mini-transposon mutants of Bordetella bronchiseptica exhibit altered abilities to invade and survive in eukaryotic cells
  77. Available carbon source influences the resistance of Neisseria meningitidis against complement
  78. Optimization of Virulence Functions Through Glucosylation of Shigella LPS
  79. Finding your niche: what has been learnt from STM studies on GI colonization
  80. An aromatic amino acid auxotrophic mutant ofBordetella bronchisepticais attenuated and immunogenic in a mouse model of infection
  81. High throughput in vivo screens: Signature-tagged mutagenesis
  82. Role of Phosphoglucomutase of Bordetella bronchiseptica in Lipopolysaccharide Biosynthesis and Virulence
  83. A Second Two-Component Regulatory System of Bordetella bronchiseptica Required for Bacterial Resistance to Oxidative Stress, Production of Acid Phosphatase, and In Vivo Persistence
  84. Non-motile mini-transposon mutants of Bordetella bronchiseptica exhibit altered abilities to invade and survive in eukaryotic cells